Takeda Pharmaceutical Company Ltd

Asia is rapidly becoming a biomanufacturing powerhouse, with countries like China, Singapore, South Korea, and India leading the charge. These nations are investing heavily in infrastructure, fostering innovation, and improving regulatory environments to attract global biopharma investments. The Asia Pacific biopharmaceuticals market is projected to grow significantly, driven by government support, skilled workforce development, and strategic partnerships. Key initiatives include Singapore's BioPIPS, South Korea's Bio-Health Industry Promotion Plan, Australia's RNA Sector Development Plan, and India's BioE3 Policy, all aimed at enhancing biomanufacturing capabilities and positioning Asia as a global leader in the biopharma industry.

DPHARM 2024 focused on innovations in clinical trials, featuring keynotes on ROI, DCTs, AI, and patient perspectives. Panels discussed efficiency, AI use, and ecosystem approaches. Outside-industry speakers offered unique insights. Technologists showcased patient-centric services. Sponsors highlighted innovation and collaboration. DPHARM Idol Disrupt finalists presented disruptive technologies, with Power winning for its patient-matching platform. The event aimed to improve clinical trials for faster, more efficient medicine delivery.

Luxa Biotechnology appoints Keith Dionne, Ph.D. as CEO to advance RPESC therapy for dry AMD/GA, aiming to restore vision for patients lacking treatment options.

DelveInsight's 'Breast Cancer Pipeline Insight 2024' highlights a robust pipeline with 100+ companies developing 120+ drugs, driven by rising incidence, tech advancements, and increased awareness. Key companies and drugs include Ambrx, CSPC ZhongQi, Merus, and ARX788, DP303c, SHR-A1811, among others. FDA fast-track designations and breakthrough therapy designations for drugs like 9MW2821 and inavolisib underscore significant progress.

S.B., A.D., T.J.F., I.M.G., L.G., R.K.J., G.K., J.M.L., G.V.L., K.P.-J., H.I.S., J.T., R.R.W., M.W., Y.L.W. have disclosed various financial interests, including funding, advisory roles, patents, and equity. C.M.B., E.B., M.W.B., and K.P. declare no competing interests.

Celiac disease, affecting 1% globally, damages small intestine villi via gluten ingestion, leading to nutrient malabsorption and serious health issues. CNP-101/TAK-101, a novel nanoparticle, showed promise in a Phase 2 trial by reducing inflammation and protecting against gluten damage, leading to Takeda acquiring its license for further development.

Swissmedic to decide by end of 2024 on approving lecanemab, the first new Alzheimer’s drug in two decades. The decision faces challenges due to safety concerns and cost-effectiveness. Lecanemab, approved in the US, Japan, China, and South Korea, targets both symptoms and underlying causes of Alzheimer’s. The European Medicines Agency rejected it, citing risks, while the UK authorized it but denied reimbursement. Swissmedic's decision will impact Alzheimer’s patients and drugmakers' investment in new treatments.